Valuation: Alps Group Inc

Market Cap 166M 143M 133M 122M 229M 15.92B 232M 1.58B 614M 8B 625M 611M 26.45B P/E 2024
-226x
P/E 2025 -277x
Enterprise Value 173M 148M 139M 127M 238M 16.54B 241M 1.64B 638M 8.31B 649M 635M 27.49B EV / Sales 2024
36.6x
EV / Sales 2025 15.2x
Free-Float
27.04%
Yield 2024 *
-
Yield 2025 -
1 day-8.66%
1 week-15.62%
Current month-34.19%
1 month-42.71%
3 months-59.90%
6 months-70.33%
Current year-68.94%
1 week 0.23
Extreme 0.22925
0.32
1 month 0.23
Extreme 0.22925
0.47
Current year 0.23
Extreme 0.22925
1.39
1 year 0.23
Extreme 0.22925
15
3 years 0.23
Extreme 0.22925
15
5 years 0.23
Extreme 0.22925
15
10 years 0.23
Extreme 0.22925
15
Date Insider Type Main position Quantity % Market Cap.
06/12/21 Other

Director and CEO; Director

15,000 -
06/12/21 Other

Director

5,000 -
06/12/21 Other

Director

5,000 -
Change 5-day change 1-year change 3-year change Capi.($)
-8.66%-15.62%-97.70%-97.46% 53.25M
-1.57%+0.12%+20.03%+36.97% 18.12B
+0.10%-1.40%+10.84%+76.87% 13.06B
-0.50%-2.65%-2.05%+71.58% 11.87B
-2.91%-4.36%-37.84%-52.43% 11.48B
-0.21%-1.19%+4.08%+83.97% 10.37B
+3.60%+2.51% - - 9.83B
+0.51%+2.05%-5.24%-29.56% 9.68B
+3.97%0.00%-10.88% - 7.62B
-2.00%-1.58%+14.49%-9.46% 7.42B
Average -0.77%-1.63%-11.59%+10.06% 9.95B
Weighted average by Cap. -0.13%-0.17%+0.63%+29.62%

Financials

2024 2025
Net sales 2.4M 2.06M 1.93M 1.76M 3.31M 230M 3.35M 22.76M 8.88M 116M 9.03M 8.83M 382M 3.37M 2.89M 2.7M 2.47M 4.64M 323M 4.7M 31.92M 12.45M 162M 12.66M 12.38M 536M
Net income -2.31M -1.98M -1.85M -1.7M -3.18M -221M -3.23M -21.9M -8.54M -111M -8.68M -8.5M -368M -2.51M -2.15M -2.01M -1.84M -3.46M -240M -3.51M -23.8M -9.28M -121M -9.44M -9.23M -400M
Net Debt -1.64M -1.41M -1.32M -1.21M -2.26M -157M -2.29M -15.56M -6.07M -78.99M -6.17M -6.04M -261M 6.49M 5.56M 5.2M 4.76M 8.94M 621M 9.06M 61.47M 23.97M 312M 24.37M 23.84M 1.03B
Logo Alps Group Inc
Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. The Company has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The Company provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. It operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
Employees
-
Date Price Change Volume
21/08/26 US$0.3200 +18.52% 65,120
20/08/26 US$0.2700 0.00% 118,613
19/08/26 US$0.2700 -8.66% 59,473
18/08/26 US$0.2956 -7.68% 123,076
17/08/26 US$0.3202 +0.06% 31,740
  1. Stock Market
  2. Stocks
  3. ALPS Stock